William Blair & Company’s Trillium Therapeutics Inc. TRIL Stock Holding History

William Blair & Company’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,150	Closed	-$442K	–	2046
2021 Q3	$442K	Sell	25,150 -109,190	-81%	-$1.28M	﹤0.01%	1198
2021 Q2	$1.3M	Sell	134,340 -116,714	-46%	-$1.1M	﹤0.01%	831
2021 Q1	$2.7M	Sell	251,054 -40,133	-14%	-$496K	0.01%	600
2020 Q4	$4.28M	Sell	291,187 -47,583	-14%	-$686K	0.02%	470
2020 Q3	$4.81M	Buy	338,770 +104,215	+44%	+$1.04M	0.02%	410
2020 Q2	$1.9M	Buy	+234,555	New	+$1.45M	0.01%	567

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

William Blair & Company's TRIL Position: Q4 2021 in Review

William Blair & Company sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 25,150 shares — an estimated $442K sold.

William Blair & Company first reported a position in TRIL in Q2 2020 and held it in 6 quarters. The position peaked at $4.81M in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

William Blair & Company reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
William Blair & Company sold 25,150 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $442K.
William Blair & Company first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 6 quarters.
William Blair & Company's Trillium Therapeutics Inc. position peaked at $4.81M in Q3 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on William Blair & Company's 13F filing for Q4 2021, filed 14 Feb 2022.